Increased von Willebrand Factor to ADAMTS13 Ratio as a Predictor of Thrombotic Complications Following a Major Hepatectomy

Kobayashi, Shinichiro; Yokoyama, Yukihiro; Matsushita, Tadashi; Kainuma, Motoshi; Igami, Tsuyoshi; Sugawara, Gen; Takahashi, Yu; Nagino, Masato

doi:10.1001/archsurg.2012.998

Cited by 22 publications

(29 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1b). ADAMTS13 activity decreased in the first week after PH, with the lowest activity on POD 7 (24 (16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32) per cent); P = 0⋅049 versus PPPD), and levels on POD 30 (42 (28-50) per cent) were still lower than before surgery. After PPPD, median ADAMTS13 activity also decreased in the first week, but was not as pronounced as following PH; ADAMTS13 activity was similar to preoperative levels on day 30 (65 (54-84) per cent) (Fig.…”

Section: Changes In the Vwf-adamts13 Axismentioning

confidence: 90%

Balance between von Willebrand factor and ADAMTS13 following major partial hepatectomy

Groeneveld

Alkozai

Adelmeijer

et al. 2016

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

Section: Changes In the Vwf-adamts13 Axismentioning

confidence: 90%

Balance between von Willebrand factor and ADAMTS13 following major partial hepatectomy

Groeneveld

Alkozai

Adelmeijer

et al. 2016

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…The interrelationship and calculated ratio between ADAMTS‐13 and VWF are also of particular interest. This topic has recently been studied in several settings and has been shown to be of potential use for predicting survival in patients with lung cancer or thrombotic complications in patients after hepatectomy …”

Section: Introductionmentioning

confidence: 99%

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study

Obermeier

Riedl

et al. 2019

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Cancer is associated with increased risk of developing venous thrombosis. Cancer patients were studied for ADAMTS‐13 and VWF levels and occurrence of venous thrombosis. Increased VWF in cancer patients is associated with a higher risk of venous thrombosis. Low levels of ADAMTS‐13 and/or increased VWF in cancer patients are associated with worse survival. Background Cancer‐associated venous thromboembolism (VTE) is an important complication in the course of a malignant disease. Low ADAMTS‐13 (a disintegrin‐like and metalloproteinase with thrombospondin type 1 motif 13) and increased von Willebrand Factor (VWF) levels in cancer patients have been described numerously. Objectives Investigation of the influence of ADAMTS‐13 and VWF on the probability of VTE and survival in malignancy. Patients/Methods In the framework of the ongoing prospective Cancer and Thrombosis Study (CATS) ADAMTS‐13 activity and VWF antigen levels were investigated in cancer patients. Results In total, 795 patients with various tumor types (364 female/431 male, median age 62 years) were included; of those, 56 developed VTE and 359 patients died during a median follow‐up time of 730 days. The hazard ratio (HR) of VTE per doubling of VWF level was 1.56 (95% confidence interval [CI] 1.13‐2.16) in multivariable competing risk analysis. ADAMTS‐13 levels showed no correlation with the incidence of VTE in univariate competing risk analysis. The HR of mortality per doubling of VWF level was 1.46 (95% CI 1.28‐1.66) and per SD increment of ADAMTS‐13was 0.90 (95% CI 0.81‐1.00) in multivariable Cox regression analysis. Patients with VWF >75th percentile and concomitant low (<25th percentile) or medium (25‐75th percentile) ADAMTS‐13 values had the highest probability of mortality (HR 4.31 and 4.75, respectively). Conclusions High VWF levels were significantly associated with the risk of developing VTE in cancer patients, whereas ADAMTS‐13 was not. Low ADAMTS‐13 and increased VWF levels were independently associated with worse overall survival.

show abstract

“…It has previously been demonstrated that a VWF/ADAMSTS13 unbalance might contribute to the risk of perioperative thrombotic complications . In addition, in living donor liver transplantation perioperative ADAMTS13 deficiency has been associated with early graft dysfunction, which might be related to intrahepatic microthrombosis .…”

Section: Discussionmentioning

confidence: 99%

Evidence for a rebalanced hemostatic system in pediatric liver transplantation: A prospective cohort study

Werner

Meijer

Adelmeijer

et al. 2020

American Journal of Transplantation

View full text Add to dashboard Cite

Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with thrombospondin motifs type 13; APTT, activated partial thromboplastin time; CLT, clot lysis time; ETP, endogenous thrombin potential; IQR, interquartile ranges; MELD score, model for end-stage liver disease score; PAI-1, plasminogen activator inhibitor type 1; PELD score, pediatric end-stage liver disease score; PT, prothrombin time; VWF, von Willebrand factor.

show abstract

Increased von Willebrand Factor to ADAMTS13 Ratio as a Predictor of Thrombotic Complications Following a Major Hepatectomy

Cited by 22 publications

References 25 publications

Balance between von Willebrand factor and ADAMTS13 following major partial hepatectomy

Balance between von Willebrand factor and ADAMTS13 following major partial hepatectomy

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study

Evidence for a rebalanced hemostatic system in pediatric liver transplantation: A prospective cohort study

Contact Info

Product

Resources

About